ConductScience.org, home

Comparison · NCT01539226-14e85045

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;. Trial comparisons, record NCT01539226-14e85045. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01539226-14e85045

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03290.02450.0441wilson
Risk in group 20.03070.01990.0469wilson
Risk difference, group 1 minus group 20.00225-0.0160.0177newcombe hybrid score
Risk ratio, group 1 over group 21.070.6371.81log
Odds ratio, group 1 over group 21.080.6281.84log
Number needed to treat, for one more participant with the outcome on Dapivirine Vaginal Ring than on Placebo Vaginal Ring444from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dapivirine Vaginal RingVaginal Ring containing 25mg of Dapivirine~Dapivirine Vaginal Ring, 25 mg: Dapivirine Vaginal Ring containing 25 mg of dapivirine431,306OG000
Group 2Placebo Vaginal RingVaginal Ring containing 0.0 mg Dapivirine~Placebo Vaginal Ring: Dapivirine Vaginal Ring containing 0.0 mg of dapivirine20652OG001

Outcome

Type
SECONDARY
Title
Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;
Description
The percentage of participants with pregnancies in each treatment group. For each treatment group, the numerator will include the number of participants that had a positive urine pregnancy test during the trial period.
Time frame
24 months
Population
The safety population included all participants who had been randomized to IP and used at least one DVR or placebo ring.

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
NCT number
NCT01539226
Phases
NA
Conditions
HIV Infections
Interventions
Placebo Vaginal Ring, Dapivirine Vaginal Ring, 25 mg
Lead sponsor
International Partnership for Microbicides, Inc.
Results first posted
2022-10-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01539226-14e85045